Important note

This AI stock analysis for Alnylam Pharmaceuticals is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Alnylam Pharmaceuticals - AI Stock Analysis

Analysis generated November 5, 2024

Alnylam Pharmaceuticals is a biopharmaceutical company dedicated to transforming the lives of those suffering from genetic disorders. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam leverages its RNA interference (RNAi) therapeutics platform to develop transformative medicines. As of recent years, the company has significant progress in its pipeline, with approved products and multiple late-stage clinical trials.

Fundamental Analysis

Alnylam Pharmaceuticals has shown impressive growth metrics over the last quarter. The revenue for the last quarter was $660 million, reflecting a robust increase of 43.73% compared to the previous quarter. Year over year, this signifies an astounding 128.54% growth compared to the same quarter last year. This consistent revenue uptick reveals a strengthening financial position.

Net income for the last quarter stood at $17 million, which is an increase of 74.39% from the previous quarter and 93.88% year over year. This increase in profitability indicates that the company is efficiently managing its operations and controlling costs.

The EBITDA for the last quarter was $64 million, an incredible increase of 312.64% from the previous quarter and a 126.05% rise compared to the same quarter last year. EBITDA growth signifies robust operational performance and the ability to generate cash flow from core operations.

However, it's also noteworthy that some company insiders have been selling their stock recently, which is often viewed as a potentially bearish signal, suggesting that some executives might feel the stock is overvalued or that growth may moderate.

Technical Analysis

Current stock price for Alnylam Pharmaceuticals is $267.56. The price has decreased by 0.16% over the past month, which could be a short-term concern. However, looking at the broader picture, the price has increased by 60.07% over the past year, which indicates a strong long-term upward trend.

The trend is currently bearish, with the SMA10 at 276.38 compared to the previous value of 278.11, suggesting that momentum may be weaker in the short term. The RSI stands at 46.8, indicating a neutral condition but closer to the lower end, potentially pointing to oversold conditions.

Alternative Data Analysis

From an alternative data perspective, there are several indicators that present a mixed view. The number of open positions at Alnylam Pharmaceuticals is 80, which is down by 18% in the last couple of months. This reduction may indicate cost-cutting measures or a slowdown in growth. Employee sentiment remains neutral, which suggests that the workplace environment and outlook have not dramatically shifted, for better or worse.

Customer acquisition metrics reveal a downturn with an estimated 39,000 visitors to their webpage, down by 24% in the last couple of months. This could indicate a potential loss in customer interest or engagement, a bearish sign for future growth.

Customer engagement on social media portrays a sliver of positive news: Instagram followers increased by 9%, indicating heightened interest. Twitter followers remain steady at 17,000, showing neither significant growth nor decline.

Finally, Alnylam Pharmaceuticals has an AI score of 75 from AltIndex, suggesting a buy signal based on comprehensive analysis across fundamental, technical, and alternative data.

Conclusion and Recommendation

Alnylam Pharmaceuticals shows strong fundamentals with growing revenue, net income, and EBITDA reflecting solid financial health and operational efficiency. The technical analysis suggests a bearish short-term trend but a strong long-term upward movement. Alternative data provides a mixed outlook, indicating potential challenges in cost management and customer acquisition but modest growth in social media engagement.

Given the overall data, coupled with a favorable AI score of 75, suggesting a buy signal, Alnylam Pharmaceuticals presents a promising investment, particularly for long-term investors. Despite some short-term concerns, the company's growth trajectory and robust fundamentals make it a viable candidate for investment. Therefore, the recommendation is to buy Alnylam Pharmaceuticals stock, especially focusing on long-term gains.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.